InVisionSeq™ is a qualitative laboratory developed test that uses targeted advanced sequencing technology to detect single nucleotide variants (SNVs), copy number variants (CNVs), insertions and deletions (InDels) in selected genes from DNA isolated from plasma samples from patients.

InVisionSeq™ is available world-wide for both commercial and research use for a range of cancer types. This test is not reimbursed in the US.

AKT1 ALK BRAF CCND1 CDKN2A CTNNB1
EGFR ERBB2 (HER2) ESR1 FGFR1 FGFR2 FGFR3
GATA3 GNA11 GNAQ GNAS HRAS IDH1
IDH2 KIT KRAS MAP2K1 MET MYC
NFE2L2 NRAS NTRK1 NTRK3 PDGFRA PIK3CA
PPP2R1A PTEN ROS1 STK11 TP53 U2AF1
SNVs + Indels - Hotspot Regions
SNVs + Indels - Exon Coverage 70% for PTEN, 88-100% for TP53, STK11 and CDKN2A
CNVs + SNVs + Indels
CNVs only

Our Technology

Our Solutions

Latest News